JP2020524660A - Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド - Google Patents

Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド Download PDF

Info

Publication number
JP2020524660A
JP2020524660A JP2019566833A JP2019566833A JP2020524660A JP 2020524660 A JP2020524660 A JP 2020524660A JP 2019566833 A JP2019566833 A JP 2019566833A JP 2019566833 A JP2019566833 A JP 2019566833A JP 2020524660 A JP2020524660 A JP 2020524660A
Authority
JP
Japan
Prior art keywords
phenyl
methylsulfonyl
dihydro
isoindole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019566833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524660A5 (https=
Inventor
サラ・リバー
フランク・ナルイェス
ロイネ・インゲマル・オルソン
シュテファン・フォン・ベルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2020524660A publication Critical patent/JP2020524660A/ja
Publication of JP2020524660A5 publication Critical patent/JP2020524660A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2019566833A 2017-06-14 2018-06-13 Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド Ceased JP2020524660A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762519263P 2017-06-14 2017-06-14
US62/519,263 2017-06-14
PCT/EP2018/065712 WO2018229155A1 (en) 2017-06-14 2018-06-13 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators

Publications (2)

Publication Number Publication Date
JP2020524660A true JP2020524660A (ja) 2020-08-20
JP2020524660A5 JP2020524660A5 (https=) 2021-07-26

Family

ID=62684777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019566833A Ceased JP2020524660A (ja) 2017-06-14 2018-06-13 Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド

Country Status (5)

Country Link
US (2) US11034654B2 (https=)
EP (1) EP3638661A1 (https=)
JP (1) JP2020524660A (https=)
CN (1) CN110730780A (https=)
WO (1) WO2018229155A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020035557A1 (en) * 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
WO2020035556A1 (en) * 2018-08-17 2020-02-20 Leo Pharma A/S Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma
CN113773251B (zh) * 2020-05-15 2024-06-11 励缔(杭州)医药科技有限公司 可用作RORγ调节剂的苯胺类化合物
CN113717090B (zh) * 2021-08-31 2022-04-05 南京林业大学 一种含三氟甲基全碳季碳中心吲哚乙腈化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2015002231A1 (ja) * 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
US20160122318A1 (en) * 2014-11-05 2016-05-05 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ror-gamma

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414139D0 (en) 1994-07-13 1994-08-31 Smithkline Beecham Plc Novel compounds
JP2000504014A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
EP1062216A1 (en) 1998-02-25 2000-12-27 Genetics Institute, Inc. Inhibitors of phospholipase a2
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
JP2004500332A (ja) 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
WO2002046164A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic compounds
AU2002236830A1 (en) 2001-01-26 2002-08-06 Chugai Seiyaku Kabushiki Kaisha Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US20050171084A1 (en) 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
AU2003227689A1 (en) 2002-04-29 2003-11-17 Novartis Ag Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
US20060189693A1 (en) 2003-07-22 2006-08-24 Barone Frank C Methods of treatment with lxr agonists
EP1653938A2 (en) 2003-07-28 2006-05-10 Glaxo Group Limited Methods of treatment of inflammatory bowel disease with lxr agonists
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
WO2007055374A1 (ja) 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
PE20071025A1 (es) 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
JP2009542803A (ja) 2006-07-12 2009-12-03 アストラゼネカ・アクチエボラーグ 鎮痛剤としての３−オキソイソインドリン−１−カルボキサミド誘導体
TW200812962A (en) 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
PL2076260T3 (pl) 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
JP4834699B2 (ja) 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
JP4846769B2 (ja) 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
WO2012027965A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012028100A1 (en) 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
WO2012100732A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof
WO2012100734A1 (en) 2011-01-24 2012-08-02 Glaxo Group Limited Compounds useful as retinoid-related orphan receptor gamma modulators
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
WO2013100027A1 (ja) 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2844247A4 (en) 2012-04-20 2015-11-25 Anderson Gaweco ROR MODULATORS AND ITS USES
EP2844259A4 (en) 2012-04-30 2015-11-11 Anderson Gaweco MMR MODULATORS AND USES THEREOF
WO2013166015A1 (en) 2012-04-30 2013-11-07 Anderson Gaweco Ror modulators and their uses
WO2013171729A2 (en) 2013-01-08 2013-11-21 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl amide compounds as rorgamat modulator
WO2014125426A1 (en) 2013-02-15 2014-08-21 Aurigene Discovery Technologies Limited Trisubstituted heterocyclic derivatives as ror gamma modulators
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
EP2991994B1 (en) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Thiazolopyrrolidine inhibitors of ror-gamma
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
EP3027616B1 (en) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Azaindole compounds as modulators of rorc
EP3041821B1 (en) 2013-09-05 2018-05-30 Boehringer Ingelheim International GmbH Bicylic compounds as modulators of rorgamma
UA117941C2 (uk) 2013-12-05 2018-10-25 Лід Фарма Холдінг Б.В. МОДУЛЯТОРИ ROR-ГAMMA (RORγ)
WO2015083130A1 (en) 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
WO2015101928A1 (en) 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Fused thiophene and thiazole derivatives as ror gamma modulators
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
JPWO2015129853A1 (ja) 2014-02-27 2017-03-30 東レ株式会社 環状アミン誘導体及びその医薬用途
WO2015145371A1 (en) 2014-03-27 2015-10-01 Piramal Enterprises Limited Ror-gamma modulators and uses thereof
KR102410076B1 (ko) 2014-04-14 2022-06-22 베링거 인겔하임 인터내셔날 게엠베하 Ror 감마의 조절제로서의 화합물
US9718817B2 (en) 2014-04-16 2017-08-01 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ROR gamma modulators
KR20170016987A (ko) 2014-07-01 2017-02-14 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물 및 이들의 레티노이드-관련 희귀 수용체 (ｒｏｒ) 감마-ｔ 저해제로서의 용도
HRP20220522T1 (hr) 2014-08-04 2022-06-10 Nuevolution A/S Proizvoljno kondenzirani heterociklil-supstituirani derivati pirimidina koji su korisni za liječenje upalnih, metaboličkih, onkoloških i autoimunih bolesti
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2016073633A1 (en) 2014-11-05 2016-05-12 University Of Kansas SMALL MOLECULE INHIBITORS OF THE MITOCHONDRIAL PERMEABILITY TRANSITION PORE (mtPTP)
US20180110774A1 (en) 2015-04-28 2018-04-26 Stc. Unm Compositions and methods for treatment of pulmonary hypertension
SMT202100286T1 (it) 2015-05-15 2021-07-12 Aurigene Discovery Tech Ltd Composti di tetraidrochinolinone sostituito come modulatori ror-gamma
EP3101005A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101008A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101006A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101009A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
EP3101007A1 (en) 2015-06-05 2016-12-07 Lead Pharma Cel Models IP B.V. Ror gamma (rory) modulators
WO2017010399A1 (ja) 2015-07-10 2017-01-19 塩野義製薬株式会社 ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
EP3356366B1 (en) 2015-10-01 2019-08-28 Boehringer Ingelheim International GmbH Pteridine derivatives as modulators of ror gamma
CN109071516B (zh) 2015-12-15 2021-08-31 阿斯利康(瑞典)有限公司 新颖的化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2015002231A1 (ja) * 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
US20160122318A1 (en) * 2014-11-05 2016-05-05 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ror-gamma

Also Published As

Publication number Publication date
US20210380533A1 (en) 2021-12-09
WO2018229155A1 (en) 2018-12-20
EP3638661A1 (en) 2020-04-22
US20200115338A1 (en) 2020-04-16
CN110730780A (zh) 2020-01-24
US11034654B2 (en) 2021-06-15

Similar Documents

Publication Publication Date Title
RU2757457C2 (ru) Пирролопиримидины в качестве потенциаторов мвтр
US11453644B1 (en) Compounds
IL297499A (en) Transmuted aminothiazoles as dgkzeta inhibitors for immune activation
EP3596052B1 (en) Chemical compounds
AU2014212426A1 (en) Quinoline and Quinoxaline Amides as Modulators of Sodium Channels
US20210380533A1 (en) 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
CN106928203A (zh) 作为激酶抑制剂的杂环酰胺
RS64376B1 (sr) Derivati benzhidroksaminske kiseline kao selektivni inhibitori hdac6
EP3704106A1 (en) Alkene compounds as farnesoid x receptor modulators
KR102519948B1 (ko) 암 치료용 화합물 및 조성물
CN112218857A (zh) P300/cbp hat抑制剂及其使用方法
CA2507186A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
CN102413694B (zh) 可用作faah调节剂和faah成像剂的咪唑衍生物
HK1260286B (zh) 新颖的化合物
HK1256181A1 (en) Isoindole compounds
HK1256181B (en) Isoindole compounds
HK1260286A1 (en) Isoindole compounds
HK40021786B (en) Chemical compounds
HK40021786A (en) Chemical compounds
BR112019010167B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr
HK40003735B (zh) 用於egfr降解的双功能分子和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210527

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220421

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220517

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220927